At 10:38, the flagship CAC 40 index grabbed 0.13% to 7,442.36 points. The Parisian rating had recovered 1.26% on Friday to close a week in the final negative.

The U.S. job market unexpectedly rebounded in April, with job creation up and unemployment falling.

These figures are both positive, as they confirm the resilience of the US economy, and at the same time a sign that the fight against high inflation in the United States is still far from over.

Investors are now waiting for the US consumer price index for April, which will be published on Wednesday, and producer prices in the United States on Thursday, to get an idea of the evolution of inflation and better anticipate the next monetary policy move of the US central bank (Fed). They will also follow China's inflation figures on Thursday.

"On Wednesday, the latest U.S. inflation figures will be released and should give another indication of the need for further interest rate hikes by the Fed. Before the weekend, the April labour market report was already moving in this direction," said Jürgen Molnar of RoboMarkets.

If inflation remains higher, the Federal Reserve may be tempted not to interrupt its rate hike cycle.

Economic activity on both sides of the Atlantic has begun to slow.

Industrial production fell in Germany in March, weighed down by the auto sector, according to figures released Monday.

It follows the wrong signal from other German economic indicators released this month.

The data plunged "surprisingly," according to Carsten Brzeski, an analyst at ING direct, increasing the chances of a "downward revision of growth in the first quarter," he added.

The German government is forecasting growth of 0.4% for the whole of 2023.

OL Group suspended

OL Groupe shares were suspended on the Paris Stock Exchange after the appointment of American John Textor as CEO to replace Lyon's iconic chairman, Jean-Michel Aulas. John Textor bought the Rhône club last December.

Nanobiotix to the extreme

After a spectacular rebound (+157.83%) On Friday, the share of the biotech specialized in oncology Nanobiotix continued at great strides (+58.41% to 6.78 euros). The company, which has developed a nanoparticle-based formula to be injected into patients treated as part of radiotherapy, said Friday it was in "final contract negotiation" with a "major global player in the pharmaceutical industry" to support the development and commercialization of NBTXR3 in head and neck cancer.

© 2023 AFP